Acute myocardial infarction associated with initial alemtuzumab infusion cycle in relapsing-remitting multiple sclerosis.

Abstract

Alemtuzumab is an anti-CD52 monoclonal antibody used for the treatment of lymphoproliferative disorders and relapsing-remitting multiple sclerosis. We report a 30-year-old woman with relapsing-remitting multiple sclerosis who developed a type 2 non-ST elevated myocardial infarction (NSTEMI) during her first alemtuzumab infusion cycle. While acute coronary syndrome has been described with alemtuzumab in the treatment of lymphoma, alemtuzumab-associated cardiac ischemia in multiple sclerosis is uncommon and can occur in patients without cardiovascular risk factors.

• Authors: Meghan C Romba, Scott D Newsome, Justin C McArthur
• Journal: Multiple sclerosis and related disorders (Mult Scler Relat Disord) Vol. 34 Pg. 100-102 (Sep 2019) ISSN: 2211-0356 [Electronic] Netherlands
• PMID: 31252364 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2019 Elsevier B.V. All rights reserved.

Chemical References

• Immunologic Factors
• Alemtuzumab

Topics

• Adult
• Alemtuzumab (administration & dosage, adverse effects)
• Female
• Humans
• Immunologic Factors (administration & dosage, adverse effects)
• Multiple Sclerosis, Relapsing-Remitting (therapy)
• Myocardial Infarction (diagnosis, etiology, therapy)